Trials in Texas.
118 APOE4-relevant Alzheimer’s trials run in Texas — 59 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- Directly recruits APOE4 carriersNCT05880849Choline Effects - Pre-symptomatic AD
This Phase 1 trial is testing whether choline — a common dietary supplement — is safe and tolerable in people who carry the APOE4 gene and show no symptoms of…
- APOE4/4 only, closed to new enrolleesNCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Unrelated to APOE4 or Alzheimer'sNCT01644591Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
This trial tests stereotactic radiosurgery — a precise, high-dose radiation technique aimed at individual tumors — in patients whose melanoma has spread to…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Open to carriers, not 4-specificNCT02814526Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
- Unrelated to APOE4 or Alzheimer'sNCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity is collecting cerebrospinal fluid and blood samples from people at various stages of Huntington's disease, plus healthy controls, across multiple…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Open to carriers, not 4-specificNCT03082755Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
This Phase 4 trial is testing whether gabapentin enacarbil (Horizant), a drug already approved for restless legs syndrome, can reduce nighttime agitation in…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, genotype not trackedNCT03113461MCI: CPAP Treatment of OSA (Memories2)
This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild…
- Observational only, genotype not requiredNCT03136679Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease
This study is collecting blood and urine samples from people with varying degrees of cognitive impairment to search for new biological markers that might…
- Observational study, genotype not a factorNCT03403257Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)
This is an observational study, not a treatment trial. Researchers are tracking how often cognitive impairment and dementia occur in Mexican American adults…
- Open to carriers, not 4-specificNCT03493178Glutathione in Mild Cognitive Impairment
This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (NAC), can raise glutathione levels in people with mild cognitive…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Open to carriers, not 4-specificNCT03750409Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia
This trial is testing whether a light-emitting helmet that delivers infrared and near-infrared light to the brain can support brain cell activity and…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04629495Rapamycin - Effects on Alzheimer's and Cognitive Health
This Phase 2 trial is testing rapamycin, a drug already approved for organ transplant patients, to see if it is safe and tolerable for people with amnestic…
- Genotype collected, carriers not excluded yetNCT04639050Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
This Phase 1 trial is testing a drug called RO7126209 — given by IV infusion — in people with early to moderate Alzheimer's who have confirmed amyloid buildup…
- Open to carriers, not 4-specificNCT04740580Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
This trial is testing whether two dietary supplements, glycine and N-acetylcysteine (together called GlyNAC), can improve brain metabolism, reduce…
- Observational only, genotype not targetedNCT04743466Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
This study looks at existing health records and biobank data to see whether low testosterone levels are linked to higher rates of dementia, depression, and…
- No Alzheimer's or APOE4 relevanceNCT04793776Manage Emotions to Reduce Aggression (MERA)
This trial tests a 3-session behavioral therapy called MERA — Manage Emotions to Reduce Aggression — against a control therapy in veterans with PTSD who…
- Not relevant to APOE4 riskNCT04881617Treatment for Speech and Language in Primary Progressive Aphasia
This trial is testing two speech-language therapies for people with primary progressive aphasia, a neurological condition that slowly erodes the ability to…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Not relevant to APOE4 carriersNCT05184569Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
This Phase 1 trial is testing whether verdiperstat, a drug that may reduce harmful inflammation in brain cells, is safe and tolerable for people with semantic…
- Non-drug study, genotype not consideredNCT05235113Remote Game-based Exercise Program for Cognitive and Motor Function Improvement
This trial tests a remote, game-based exercise platform — called a tele-exergame system — designed to improve balance and cognitive function in older adults…
- Unrelated to APOE4 carriersNCT05326451Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
This trial is testing a brain stimulation device called tDCS — transcranial direct current stimulation — delivered at home by people with Huntington's disease…
- Open to carriers, not 4-specificNCT05331144Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
This Phase 2 trial is testing whether aggressively lowering systolic blood pressure — using two common prescription medications, losartan and amlodipine —…
- Imaging study, genotype not requiredNCT05361382Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
This trial is comparing two different PET scan tracers — Flortaucipir and MK-6240 — that are used to measure tau tangles in the brain, a hallmark of…
- Screening registry, genotype not targetedNCT05364307Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
This is not a treatment trial. APHELEIA is a prescreening registry designed to find and evaluate people who might qualify for future Alzheimer's therapeutic…
- Not Alzheimer-focused, genotype irrelevantNCT05368350Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
This trial is testing whether a gentle electrical current applied to specific brain regions can improve speech and language problems in people with primary…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.